MacroGenics is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. MARGENZA™ (margetuximab-cmkb) is the first product approved by the FDA from MacroGenics’ pipeline.
Brands: https://events.jspargo.com/ASCO21/CUSTOM/MacroGenics%20-%20Background%20DART_header.png
Press Releases
Products